Efficacy of CHOP and G-CSF combination treatment versus CHOP monotherapy in HIV-1 infected patient with NHL (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Efficacy of CHOP and G-CSF combination treatment versus CHOP monotherapy in HIV-1 infected patient with NHL (Meeting abstract).

Biological Response Modifiers, 2nd International Congress. January 29-31. 1993, San Diego, CA, p. 76, 1993.. Unique Identifier : AIDSLINE ICDB/94698348
Gori A; Ridolfo AL; Romaniello A; Franzetti F; Coppin P; Formenti T; Gervasoni C; d'Arminio Monforte A; Moroni M; Clinic of Infectious Diseases, Univ. of Milan, Italy

Abstract: Objective: To evaluate whether G-CSF and CHOP treatment in HIV-1 infected patients with high-grade NHL allows a better adherence to the therapeutic schedule as compared to patients treated with CHOP alone. Methods: We evaluated retrospectively 6 patients treated with CHOP compared with 8 patients treated with CHOP associated with G-CSF (5 g/kg/day sc from 8th to 21st day of each cycle). In each group, we evaluated the number of cycles, the pauses between cycles, the necessity of drug dosage reduction, the degree of leukopenia at nadir, the duration of neutropenia (ANC less than 1000/mm3), the days of fever and the number of infectious episodes. Results are presented in a table. Conclusions: These preliminary data show that the patients treated with the association of G-CSF and chemotherapy withstand a greater number of cycles of therapy, at full doses and regular pauses, experiencing a reduction of the days of neutropenia, fever and infectious episodes.

Keywords: Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE Cyclophosphamide/ADMINISTRATION & DOSAGE Doxorubicin/ADMINISTRATION & DOSAGE Fever/CHEMICALLY INDUCED/DRUG THERAPY Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE Human HIV Infections/COMPLICATIONS/*DRUG THERAPY Leukopenia/CHEMICALLY INDUCED/DRUG THERAPY Lymphoma, Non-Hodgkin's/COMPLICATIONS/*DRUG THERAPY Neutropenia/CHEMICALLY INDUCED/DRUG THERAPY Prednisone/ADMINISTRATION & DOSAGE Vincristine/ADMINISTRATION & DOSAGE ABSTRACT
940530
M9450891

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .